Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
Go back to Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026| (NASDAQ: KURA) | Delayed: 10.38 +0.02 (0.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.36 | 52 Week High | $8.90 | |||
| Open | $10.18 | 52 Week Low | $2.50 | |||
| Day High | $10.66 | P/E | N/A | |||
| Day Low | $10.18 | EPS | $0.00 | |||
| Volume | 1,112,961 | |||||
